Last reviewed · How we verify
Thymanax (AGOMELATINE)
Thymanax (Agomelatine) is a small molecule drug developed by Les Laboratoires Servier, targeting the melatonin receptor type 1A. It is classified as an agomelatine and is approved for the treatment of major depressive disorder. The commercial status of Thymanax is patented, and it is owned by Les Laboratoires Servier. Key safety considerations include its potential effects on liver function and the need for regular monitoring. Thymanax is not FDA-approved.
At a glance
| Generic name | AGOMELATINE |
|---|---|
| Sponsor | Les Laboratoires Servier |
| Drug class | agomelatine |
| Target | Melatonin receptor type 1A |
| Modality | Small molecule |
| Therapeutic area | Neuroscience |
| Phase | FDA-approved |
| First approval | 2009 |
Approved indications
- Major depressive disorder
Common side effects
Key clinical trials
- Switching Medication and Augmentation Strategies for SSRI-Resistant Adolescent Depression（SMART-I) (PHASE4)
- A Study of Esketamine Nasal Spray Plus a New Standard-of-care Oral Antidepressant or Placebo Nasal Spray Plus a New Standard-of-care Oral Antidepressant in Adult and Elderly Participants With Treatment-resistant Depression (PHASE3)
- Efficacy of Agomelatine in Patients With Obsessive-Compulsive Disorder (PHASE2)
- A Double-blind, Placebo-controlled Study of Antidepressant Augmentation With Agomelatine (PHASE4)
- CYP1A2, ABCB1, CYP2C9 and Plasma Concentration of Agomelatine in Adult Patients With Depression
- Multimodal Magnetic Resonance Imaging-based Study of Electroconvulsive Efficacy Prediction in Adolescents With Depression: a Multicenter Prospective Cohort Study
- Comparative Responses to 15 Different Antidepressants in Major Depressive Disorder
- A Study on the Efficacy of Agomelatine Combined With Antipsychotics to Treat Negative Symptoms in Schizophrenia (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Thymanax CI brief — competitive landscape report
- Thymanax updates RSS · CI watch RSS
- Les Laboratoires Servier portfolio CI